LON:SN - Smith & Nephew Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 1,451 -9.50 (-0.65 %)
(As of 02/17/2019 08:46 AM ET)
Previous CloseGBX 1,451
Today's RangeGBX 1,444.50 - GBX 1,464
52-Week RangeGBX 1,173 - GBX 1,442
Volume4.71 million shs
Average Volume3.25 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery, various products, and technologies to assist in surgical treatment of the ear, nose, and throat; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.

Receive SN News and Ratings via Email

Sign-up to receive the latest news and ratings for SN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Appliances & Equipment
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone+44-20-74017646

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees15,000
OptionableOptionable

Smith & Nephew (LON:SN) Frequently Asked Questions

What is Smith & Nephew's stock symbol?

Smith & Nephew trades on the London Stock Exchange (LON) under the ticker symbol "SN."

How often does Smith & Nephew pay dividends? What is the dividend yield for Smith & Nephew?

Smith & Nephew declared a dividend on Thursday, February 7th. Shareholders of record on Thursday, April 4th will be given a dividend of GBX 0.22 per share on Wednesday, May 8th. This represents a yield of 1.1%. The ex-dividend date is Thursday, April 4th. This is an increase from Smith & Nephew's previous dividend of $0.14. The official announcement can be accessed at this link. View Smith & Nephew's Dividend History.

What price target have analysts set for SN?

11 analysts have issued 12 month price targets for Smith & Nephew's stock. Their forecasts range from GBX 1,350 to GBX 1,692. On average, they anticipate Smith & Nephew's stock price to reach GBX 1,479.36 in the next year. This suggests a possible upside of 2.0% from the stock's current price. View Analyst Price Targets for Smith & Nephew.

What is the consensus analysts' recommendation for Smith & Nephew?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Smith & Nephew.

Has Smith & Nephew been receiving favorable news coverage?

Media stories about SN stock have been trending positive this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Smith & Nephew earned a coverage optimism score of 2.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the immediate future.

Who are some of Smith & Nephew's key competitors?

Who are Smith & Nephew's key executives?

Smith & Nephew's management team includes the folowing people:
  • Mr. Graham Timothy Baker, CFO & Exec. Director (Age 51)
  • Mr. Namal Nawana, CEO & Exec. Director (Age 48)
  • Mr. Mark Gladwell, Pres of Global Operations (Age 44)
  • Ms. Catheryn O'Rourke, Chief Legal & Compliance Officer (Age 46)
  • Mr. Joe Metzger, Sr. VP of Marketing Services & Communications

How do I buy shares of Smith & Nephew?

Shares of SN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Smith & Nephew's stock price today?

One share of SN stock can currently be purchased for approximately GBX 1,451.

What is Smith & Nephew's official website?

The official website for Smith & Nephew is http://www.smith-nephew.com/.

How can I contact Smith & Nephew?

Smith & Nephew's mailing address is 15 Adam Street, LONDON, WC2N 6LA, United Kingdom. The company can be reached via phone at +44-20-74017646.


MarketBeat Community Rating for Smith & Nephew (LON SN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  469 (Vote Outperform)
Underperform Votes:  578 (Vote Underperform)
Total Votes:  1,047
MarketBeat's community ratings are surveys of what our community members think about Smith & Nephew and other stocks. Vote "Outperform" if you believe SN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel